News and Announcements
Antisense Therapeutics To Undertake Clinical Trial of ALT1102 in Duchenne Muscular Dystrophy at the Melbourne Royal Children’s Hospital
- Published June 26, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Antisense Therapeutics (ANP) has announced that the company has undertaken advanced planning for the clinical trial of ALT1102, its immunomodulatory therapy initially in development for the treatment of Multiple Sclerosis (MS). The trial is designed to assess the drug’s effects on the inflammation associated with this rare and incurable muscle wasting disease of children (Duchenne Muscular Dystrophy).
KEY TAKEAWAYS:
- Company to undertake a clinical trial of its drug ATL1102 in new clinical application, Duchenne Muscular Dystrophy
- Clinical trial is planned to be undertaken at the Royal Children’s Hospital (RCH), Melbourne
- World class international advisory board established chaired by Mr William Goolsbee ANP’s non-executive director and ex-Chairman of Sarepta Therapeutics
- Funding secured for the trial (subject to receipt of approval to commence the trial)
- Australian Ethical Investment to become largest shareholder in the Company
Mark Diamond, CEO of Antisense Therapeutics said: “Our plan to undertake a clinical trial of ATL1102 in DMD patients is facilitated by the extensive pre-clinical and clinical experience that we have established via ATL1102’s development in MS. As DMD is a rare disease with a high unmet medical need, ATL1102 is expected to benefit materially from development incentives, including orphan drug designation that are provided to support rare disease drug development”.
Company Updates
Funding the Future: The Strategic Power of Venture Debt in a Volatile Market
Discover Martin Tang’s perspective on the evolving venture debt landscape in Southeast Asia, its strategic advantages over traditional VC, and its importance in navigating the current economic climate.
From Desert to Dairy: How Australia’s Wild Camels and Good Earth Dairy’s Technology are Transforming Infant Formula
“In the heart of Australia’s outback, an innovative dairy company is harnessing the world’s largest wild camel population to revolutionise infant nutrition, targeting the rapidly growing AUD $127B global infant formula market with hypoallergenic solutions.
World-First FDA Approval for EBR Systems’ Leadless Cardiac Device Opens US$3.6bn Market
Discover how EBR Systems’ groundbreaking WISE CRT System, the first leadless left ventricular pacing technology, has gained FDA approval, addressing limitations of traditional cardiac resynchronisation therapy.
Backed By Leading Investment Groups and Family Offices
